Chemical Component Summary

Name(S)-4,4'-(1-METHYL-1,2-ETHANEDIYL)BIS-2,6-PIPERAZINEDIONE
SynonymsICRF-187
Identifiers4-[(2R)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
FormulaC11 H16 N4 O4
Molecular Weight268.269
TypeNON-POLYMER
Isomeric SMILESC[C@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
InChIInChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1
InChIKeyBMKDZUISNHGIBY-SSDOTTSWSA-N

Chemical Details

Formal Charge0
Atom Count35
Chiral Atom Count1
Bond Count36
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00380 
NameDexrazoxane
Groups
  • approved
  • withdrawn
DescriptionAn antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
Synonyms
  • Dexrazoxanum
  • (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione
  • (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane
  • Dexrazoxan
  • Dexrazoxano
Brand Names
  • Zinecard
  • Dexrazoxane for Injection
  • Totect
  • Savene
  • Cardioxane
IndicationFor reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
Categories
  • Cardiotonic Agents
  • Cardiovascular Agents
  • Compounds used in a research, industrial, or household setting
  • Cytoprotective Agent
  • Detoxifying Agents for Antineoplastic Treatment
ATC-CodeV03AF02
CAS number24584-09-6

Drug Targets

NameTarget SequencePharmacological ActionActions
DNA topoisomerase 2-alphaMEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTY...unknowninhibitor
DNA topoisomerase 2-betaMAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLS...unknown
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 298076
ChEMBL CHEMBL1231714
CCDC/CSD ICRFRA10